Estrella Immunopharma
ESLA
23 hedge funds and large institutions have $34.3M invested in Estrella Immunopharma in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 22 → 23 (+1)
1% more capital invested
Capital invested by funds: $33.9M → $34.3M (+$400K)
0.34% more ownership
Funds ownership: 57.95% → 58.29% (+0.34%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$226K |
| 2 |
OFG
OTA Financial Group
Purchase,
New York
|
+$136K |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$31.5K |
| 4 |
EC
Elequin Capital
New York
|
+$24.1K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pinz Capital Management
New York
|
-$241K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$113K |
| 3 |
Goldman Sachs
New York
|
-$101K |
ESLA Hedge Fund Activity: Q3 2022 in Review
23 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q3 2022, worth a combined $34.3M — up 1.2% from $33.9M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ESLA positions and 2 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Karpus Investment Management, adding an estimated $226K. The largest seller was Pinz Capital Management, exiting entirely with an estimated $241K sold.
- 23 institutional investors held Estrella Immunopharma (ESLA) as of Q3 2022, up from 22 in Q2 2022.
- Funds reported $34.3M of Estrella Immunopharma stock for Q3 2022, up 1.2% quarter-over-quarter.
- 3 funds opened new Estrella Immunopharma positions in Q3 2022 and 2 closed out, a net change of +1 holder.
- The largest Estrella Immunopharma buyer in Q3 2022 was Karpus Investment Management, an estimated $226K added.
- The largest Estrella Immunopharma seller in Q3 2022 was Pinz Capital Management, an estimated $241K sold.
Based on aggregated 13F filings for Q3 2022.